SCHEMBL17216643

SCHEMBL17216643

Cc1cccc([C]=NOCc2cc(F)cc(F)c2)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACHE P22303 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ IDO1 P14902 5/20 0.35
▸ CYP1A2 P05177 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ CYP2D6 P10635 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ FFAR1 O14842 3/20 0.33
▸ P2RX7 Q99572 2/20 0.33
▸ FFAR4 Q5NUL3 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ GRM5 P41594 1/20 0.33
▸ MMP1 P03956 1/20 0.32
▸ MMP2 P08253 1/20 0.32
▸ MMP9 P14780 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17216641 1.00 ACHE (0.37) ACHESMN1; SMN2IDO1CYP1A2CYP3A4
SCHEMBL17216365 0.90 SMN1; SMN2 (0.46) ACHESMN1; SMN2IDO1P2RX7ALDH1A1
SCHEMBL17216361 0.90 SMN1; SMN2 (0.46) ACHESMN1; SMN2IDO1P2RX7ALDH1A1
SCHEMBL17216656 0.89 MAOB (0.39) ACHESMN1; SMN2IDO1MAPTHTT
SCHEMBL17216658 0.89 MAOB (0.39) ACHESMN1; SMN2IDO1MAPTHTT
SCHEMBL17216989 0.87 IDO1 (0.41) SMN1; SMN2IDO1AGXT
SCHEMBL17216987 0.87 IDO1 (0.41) SMN1; SMN2IDO1AGXT
SCHEMBL17216975 0.85 IDO1 (0.50) IDO1FFAR1GRM5MMP2MMP9
SCHEMBL17216976 0.85 IDO1 (0.50) IDO1FFAR1GRM5MMP2MMP9
SCHEMBL17216928 0.84 SMN1; SMN2 (0.35) SMN1; SMN2IDO1MAPTKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2940012-B1 TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF SUMITOMO CHEMICAL CO (JP) 2019-01-30 — — EP disclosed
US-9560850-B2 Tetrazolinone compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-02-07 — — US disclosed
US-20150336908-A1 TETRAZOLINONE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2015-11-26 — — US disclosed
EP-2940012-A1 TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF Sumitomo Chemical Company Limited (JP) 2015-11-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150336908-A1 TETRAZOLINONE COMPOUND AND USE THEREOF RTN3, CYP51A1, TCOF1 ACHE 1153/4885SMN1; SMN2 4013/4885IDO1 2882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback